




P-15574



**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)



**PCT/US 03/23270**


INVESTOR IN PEOPLE  
The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

*P. Mahoney*

Dated 26 September 2002

**BEST AVAILABLE COPY**



# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

23 AUG 2002

1. Your reference

P-15579

2. Patent application number

(The Patent Office will fill in this part)

0219687.1

3. Full name, address and postcode of the or of each applicant (underline all surnames)

ELI LILLY AND COMPANY,  
LILLY CORPORATE CENTER,  
INDIANAPOLIS,  
INDIANA 46285, USA

428904002

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

STATE OF INDIANA, U.S.A.

4. Title of the invention

BENZYL MORPHOLINE DERIVATIVES

5. Name of your agent (if you have one)

VAUGHAN, Jennifer Ann

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

LILLY RESEARCH CENTRE,  
ERL WOOD MANOR,  
WINDLESHAM,  
SURREY, GU20 6PH, UK

Patents ADP number (if you know it)

791 0276001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

YES

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 31 ✓

Claim(s) 03 ✓

Abstract 01 ✓

Drawing(s)

*QML*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

1 ✓

Request for substantive examination (*Patents Form 10/77*)

Any other documents (*please specify*)

11.

I/We request the grant of a patent on the basis of this application.

Signature

*[Signature]*

Date 23 August 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Georgina L Howard

01276 483443

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.


## BENZYL MORPHOLINE DERIVATIVES

This invention relates to novel benzyl morpholine compounds, and to their use in selectively inhibiting norepinephrine reuptake.

5 Selective inhibition of norepinephrine reuptake is a relatively new mode of action for the treatment of affective disorders. Norepinephrine appears to play an important role in the disturbances of vegetative function associated with affective, anxiety and cognitive disorders. Tomoxetine hydrochloride is a selective inhibitor of norepinephrine, and is currently under development for the treatment of attention  
 10 deficit hyperactivity disorder (ADHD). Reboxetine is a marketed selective norepinephrine reuptake inhibitor for the treatment of depression.

According to the present invention there is provided a compound of formula

(I)



15 wherein

Rx is H;

Ry is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

each Rz is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

X represents O;

20 Y represents OH or OR;

R is C<sub>1</sub>-C<sub>4</sub> alkyl; and

Ar<sub>1</sub> and Ar<sub>2</sub> are each independently selected from the group consisting of phenyl, and substituted phenyl; and pharmaceutically acceptable salts thereof.

The group Ar<sub>1</sub> may be substituted or unsubstituted phenyl. For example, Ar<sub>1</sub>  
 25 may be unsubstituted phenyl or, preferably phenyl substituted with 1, 2, 3, 4 or 5 substituents, preferably with 1 or 2, for example 1, substituent. When monosubstituted, the substituted phenyl group is preferably substituted in the 2-


position. Suitable substituents include C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo, and phenyl, optionally substituted with, for example, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, or O(C<sub>1</sub>-C<sub>4</sub> alkyl).

5 The group Ar<sub>2</sub> may be substituted or unsubstituted phenyl. For example, Ar<sub>2</sub> may be phenyl substituted with 1, 2, 3, 4 or 5 substituents, preferably with 1 substituent. Suitable substituents include C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), and especially, halo.

10 "C<sub>1</sub>-C<sub>4</sub> alkyl" as used herein includes straight and branched chain alkyl groups of 1, 2, 3 or 4 carbon atoms, and may be unsubstituted or substituted. C<sub>1</sub>-C<sub>2</sub> alkyl groups are preferred. Suitable substituents include halo. Thus the term "C<sub>1</sub>-C<sub>4</sub> alkyl" includes haloalkyl. A particularly preferred substituted C<sub>1</sub>-C<sub>4</sub> alkyl group is trifluoromethyl.

"Halo" includes F, Cl, Br and I, and is preferably F or Cl.

15 A preferred group of compounds according to the present invention is represented by the formula (II)



wherein R<sub>1</sub> and R<sub>2</sub> are each independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo and phenyl; and R<sub>3</sub> is selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl and halo; and pharmaceutically acceptable salts thereof.

20


R<sub>1</sub> is preferably C<sub>1</sub>-C<sub>3</sub> alkyl, O(C<sub>1</sub>-C<sub>3</sub> alkyl), F or Ph. R<sub>2</sub> is preferably H. R<sub>3</sub> is preferably H.

Compounds of the present invention are selective inhibitors of norepinephrine reuptake. In addition, they are acid stable. Advantageously, they have a reduced interaction with the liver enzyme CYP2D6. They are indicated for the treatment of disorders associated with norepinephrine dysfunction in mammals.

25

Compounds of the present invention may be prepared according to the following methods.


A general scheme outlining the synthetic routes to compounds of the present invention is shown below (Scheme 1).



Scheme 1


Compounds of the present invention may be prepared by conventional organic chemistry techniques from a *N*-benzyl-ketomorpholine of type 1 by addition of a suitable organometallic derivative (method A), or *via* the addition of a suitable organometallic reagent to an epoxide of type 2 (method B), as outlined in Scheme 1.

The racemic intermediates of type 1 may be obtained as outlined in Scheme 2 by condensation of a *N*-benzyl cyanomorpholine 5 (*J. Med. Chem.* 1993, 36, pp 683 – 689) with a suitable aryl organometallic reagent followed by acid hydrolysis. Chiral HPLC separations of the racemic *N*-benzyl-aryl-ketomorpholine of type 1 gives the required single enantiomers, i.e., the (2*S*)- *N*-benzyl-aryl-ketomorpholine of type 6 (Scheme 2).




Scheme 2

Condensation of a chiral (2*S*)-*N*-benzyl-aryl-ketomorpholine of type 6 with a commercially available benzylic magnesium halide or a benzylic magnesium halide prepared using standard Grignard techniques from the corresponding halo-benzylic derivative gives a tertiary alcohols of type 3 without any observed epimerisation of the existing asymmetric center (ee's/de's determinations may be carried out using chiral HPLC) and with very high overall diastereoisomeric excesses (see Scheme 3). The final compounds of type 4 may be obtained after cleavage of the *N*-benzyl protecting group on a compound of type 3. The deprotection can be done using catalytic palladium hydrogenolysis, or carbamate exchange with ACE-Cl (1-Chloroethyl chloroformate), giving intermediates of type 7, followed by methanolysis as shown in Scheme 3.



Scheme 3

The intermediates 3 may be further elaborated using for example organometallic type couplings between an ortho bromide derivative of type 8 and an arylboronic acid as shown in Scheme 4.



Scheme 4

An alternative route for the preparation of the compounds of this invention is method B (see Scheme 1). Formation of the intermediate epoxides of type 2 from racemic *N*-benzyl-ketomorpholines of type 1, may be done using for example trimethyl sulfoxonium iodide and a suitable base, for example sodium hydride.

Condensation of 2 with a commercially available aryl organometallic, or an aryl organometallic prepared from the corresponding halo aryl derivative, gives the intermediates of type 3, as mixtures of diastereoisomers. Final deprotections may be done as described above (see scheme 3). Final compounds made using method B may be purified using chiral HPLC.

In addition to the compounds of formula I and formula II, and processes for the preparation of said compounds, the present invention further provides pharmaceutical compositions comprising a compound of formula I or formula II or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

Further, the present invention provides a compound of formula I or formula II or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical; and a compound of formula I or formula II or a pharmaceutically acceptable salt thereof, for use as a selective inhibitor of the reuptake of norepinephrine.

The present compounds and salts may be indicated in the treatment of disorders associated with norepinephrine dysfunction in mammals, including affective, anxiety, and cognitive disorders.



Disorders associated with norepinephrine dysfunction in mammals include, for example, nervous system conditions selected from the group consisting of an addictive disorder and withdrawal syndrome, an adjustment disorder, an age-associated learning and mental disorder, anorexia nervosa, apathy, an attention-deficit disorder (ADD) due to general medical conditions, attention-deficit hyperactivity disorder (ADHD), bipolar disorder, bulimia nervosa, chronic fatigue syndrome, chronic or acute stress, conduct disorder, cyclothymic disorder, depression, dysthymic disorder, fibromyalgia and other somatoform disorders, generalized anxiety disorder, incontinence, an inhalation disorder, an intoxication disorder, mania, migraine headaches, obesity, obsessive compulsive disorders and related spectrum disorders, oppositional defiant disorder, panic disorder, peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, a psychotic disorder, seasonal affective disorder, a sleep disorder, social phobia, a specific developmental disorder, selective serotonin reuptake inhibition (SSRI) "poop out" syndrome, TIC disorders, cognitive disorders including mild cognitive impairment (MCI), dementia of the Alzheimers type (DAT), vascular dementia and cognitive impairment associated with schizophrenia (CIAS), hypotensive states including orthostatic hypotension, and pain including chronic pain, neuropathic pain and antinociceptive pain. The compounds of the present invention are particularly suitable for the treatment of attention deficit hyperactivity disorder, ADHD.

Thus, the present invention also provides a compound of formula I or formula II for selectively inhibiting the reuptake of norepinephrine; and a compound of formula I or formula II for treating disorders associated with norepinephrine dysfunction in mammals; and the use of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for selectively inhibiting the reuptake of norepinephrine; and the use of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of disorders associated with norepinephrine dysfunction in mammals, including the disorders listed herein.

Further, the present invention provides a method for selectively inhibiting the reuptake of norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or formula II or a

pharmaceutically acceptable salt thereof; and a method for treating disorders associated with norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or formula II or a pharmaceutically acceptable salt thereof.

5       The present invention includes the pharmaceutically acceptable salts of the compounds of formula I and formula II. Suitable salts include acid addition salts, including salts formed with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic or organic sulphonic acids, for example, acetoxybenzoic, citric,  
10   glycolic, *o*- mandelic-l, mandelic-dl, mandelic d, maleic, mesotartaric monohydrate, hydroxymaleic, fumaric, lactobionic, malic, methanesulphonic, napsylic, naphthalenedisulfonic, naphtoic, oxalic, palmitic, phenylacetic, propionic, pyridyl hydroxy pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, 2-hydroxyethane sulphonic, toluene-p-sulphonic, and xinafoic acids.


15       In addition to the pharmaceutically acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically acceptable, acid addition salts, or are useful for identification, characterisation or purification.

20       It will be appreciated that compounds of formula I and formula II possess asymmetric carbon atoms, and that in the present invention specific individual stereoisomers are preferred.

The following examples illustrate compounds of the present invention and methods for their preparation.

## 25   Stereochemical conventions

The absolute stereochemistry of the compound below was determined using x-ray crystallography.




All final compounds were obtained as single isomers either through the use of chirally pure starting materials or chiral separation methods, such as chiral HPLC.

### Synthesis of Intermediates.

5

#### Preparation of (4-Benzyl-morpholin-2-yl)-phenyl-methanone.

##### a) 4-Benzyl-morpholine-2-carbonitrile




10 A one-litre reactor with mechanical stirring, cooled by ice bath, was charged with *N*-benzylethanolamine (172.2 g ; 1 equiv.). 2-Chloroacrylonitrile (100 g; 1 equiv.) was added dropwise over 2 minutes. The temperature was maintained between 23 °C and 29 °C by means of the ice bath and subsequently a water bath at 15 °C. *N*-Benzylethanolamine was still detected on TLC after 4.5 h stirring. After one night stirring at room temperature (water bath), no *N*-benzylethanolamine was  
15 detectable by <sup>1</sup>H RMN. The mixture was dissolved in tetrahydrofuran and transferred to a 2 L reactor cooled to -5 °C by ice/NaCl bath. The total volume of tetrahydrofuran was 1.35 L. Potassium *tert*-butoxyde (148 g; 1.1 equiv.) was added by portions in 1 hour, keeping the reaction temperature at 0±2 °C. After 1 hour post-stirring at 0 °C, the mixture was quenched with saturated NaHCO<sub>3</sub> (500 mL). The  
20 aqueous layer was extracted with diethyl ether (500 mL). Organic layers were dried on MgSO<sub>4</sub> and evaporated to dryness. The title compound (149.8 g; 65%) was obtained after percolation of the 250 g dry residue on 1 kg of SiO<sub>2</sub>, eluting with the following gradient:

|                           |       |
|---------------------------|-------|
| 5% AcOEt – 95% n-heptane  | 2.5 L |
| 10% AcOEt – 90% n-heptane | 2 L   |
| 15% AcOEt – 85% n-heptane | 2 L   |

20% AcOEt – 80% n-heptane

5 L

## b) (2S)-(4-Benzyl-morpholin-2-yl)-phenyl-methanone.




A 3l double jacket reactor was charged with 4-Benzyl-morpholine-2-carbonitrile (135.05 g; 1eq) and dry diethyl ether (1.4 l). When  $T_j=0^{\circ}\text{C}$  and  $T_m=1^{\circ}\text{C}$ , phenyl magnesium chloride (2M sol. in tetrahydrofuran, 360 ml, 1.08 equiv) was added dropwise over 1 hour.  $T_m$  rose to  $4^{\circ}\text{C}$  and came back to  $2^{\circ}\text{C}$  at the end of the addition.  $T_m$  was progressively raised to  $17.5^{\circ}\text{C}$  over 45 minutes and the mixture stirred at this temperature for another 45 minutes. The reactor was cooled down to  $T_m=2^{\circ}\text{C}$  and  $T_j=0^{\circ}\text{C}$  (75 minutes) and hydrochloric acid (700ml of 5N solution) was added in two portions.  $T_m$  rose to  $33^{\circ}\text{C}$ . After some minutes, the hydrochloride salt of the ketone crystallised. When  $T_m=T_j=\text{room temperature}$ , the triphasic suspension was filtrated. The organic layer of the mother liquors was eliminated. The filtration cake was then washed with methylene chloride (700 ml). This liquor was charged in the reactor with the acid aqueous layer. Treatment of the hydrochloride salt: After drying under vacuum, 164.4 g of the hydrochloride contaminated with  $\text{MgCl}_2$  were suspended in a biphasic mixture of water/methylenchloride (500 ml/800 ml). The suspension was basified with aqueous sodium hydroxide (75 ml of a 30% solution) under ice bath cooling.  $\text{Mg}(\text{OH})_2$  precipitated and the aqueous layer was extracted with methylene chloride. The organic layers were filtrated on a bed of Celite 512 after addition of Celite. The filtrated organic phase was dried over magnesium sulphate and evaporated to dryness. The ketone crystallized readily on standing (132.4 g; 70%). Treatment of the mother liquors: The combined organic phases were washed with aqueous sodium hydroxide (750ml of a 2N solution). Celite 512 (160 g) was added to the suspension which was then filtrated through a bed of Celite. The aqueous layer was

separated and extracted with methylene chloride. The combined organic phases were dried over magnesium sulphate and evaporated to dryness to provide 35.8 g of the title compound enriched with unreacted nitrile. Chiral compound was obtained after separation using chiral HPLC on a Daicel chiralpak AD 20 $\mu$ m column with  
5 100% Ethanol / 0.3% DMEA as eluent at a flow rate of 150ml/min and UV-detection at 300nm.


Preparation of 2-Chloromethyl-4-fluoro-1-methoxy-benzene.

10 a) (5-Fluoro-2-methoxy-phenyl)-methanol.



To a solution of 2-Methoxy-5-fluorobenzaldehyde (11.093g, 1 equiv.) in methanol at -10 °C under nitrogen atmosphere was added NaBH<sub>4</sub> (7.515g, 2.7 equiv.) portionwise. The solution was allowed to warm to room temperature and  
15 after 30 minutes the reaction solvent was removed under reduced pressure and replaced with dichloromethane. This solution was poured onto ice water and further extracted with dichloromethane. The organics fractions were collected and dried (MgSO<sub>4</sub>) and the solvent removed under reduced pressure to give the title compound as an oil (9.794g, 87%).. <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>):  $\delta$  2.58 (m, 1H),  
20 3.81 (s, 3H), 4.63 (d, 2H,  $J$  = 6.3 Hz), 6.78 (dd, 1H,  $J$  = 8.9 and 4.3 Hz), 6.94 (td, 1H,  $J$  = 8.5 and 3.1Hz), 7.04 (dd, 1H,  $J$  = 8.7 and 3.1Hz).

b) 2-Chloromethyl-4-fluoro-1-methoxy-benzene.




25 Neat (5-Fluoro-2-methoxy-phenyl)-methanol (19.587g, 1 equiv.) was added to neat SOCl<sub>2</sub> (42.2 mL, 4.6 equiv.) at -78°C under a nitrogen atmosphere and the

solution was then allowed to warm to room temperature and stirred until evolution of gas had ceased. An equivalent volume of anhydrous toluene was added to the flask and the solution heated to 60°C. On cooling the reaction solution was poured onto ice water. The toluene layer was separated and dried (MgSO<sub>4</sub>) and the solvent removed under reduced pressure. The crude material was sublimed (60-80°C/0.05 mBar) to give the title compound as a white solid (13.40 g, 61%). <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 3.87 (s, 3H), 4.60 (s, 2H), 6.79-7.20 (m, 3H).


Preparation of 1-Chloromethyl-2-isopropoxy-benzene.

a) (2-Isopropoxy-phenyl)-methanol.



A mixture of 2-hydroxybenzyl alcohol (21.04g, 1 equiv.), 2-isopropyl iodide (32.3 mL, 1.9 equiv.) and K<sub>2</sub>CO<sub>3</sub> (71.42g, 3 equiv.) in ethanol was refluxed for 3 hours. On cooling the reaction mixture was filtered and the solvent removed under reduced pressure and replaced with dichloromethane, and then filtered and the solvent removed to give the title compound as an oil (27.751g, 99%). <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): δ 1.37 (d, 6H, J = 6.0Hz), 3.55 (bs, 1H), 4.50-4.70 (m, 3H), 6.78-6.90 (m, 2H), 7.15-7.25 (m, 2H).

b) 1-Chloromethyl-2-isopropoxy-benzene.



The title compound was prepared using the general procedure outlined above for the preparation of 2-Chloromethyl-4-fluoro-1-methoxy-benzene followed by the following treatment:


The crude reaction material was chromatographed on silica gel and eluted 1:9 ethyl acetate/heptane prior to distillation (40-60 °C/0.05 mBar). <sup>1</sup>H NMR

(300MHz, CDCl<sub>3</sub>):  $\delta$  1.37 (d, 6H, J = 6.0Hz), 4.50-4.70 (m, 3H), 6.80-7.00 (m, 2H), 7.23-7.30 (m, 2H).

Example 1

5 Preparation of (S, R)-2-(2-Methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride.


a) 1-(4-Benzyl-morpholin-2-yl)-2-(2-methoxy-phenyl)-1-phenyl-ethanol.



10 Solid magnesium turnings (9.5 g, 28 equiv.) under nitrogen atmosphere at room temperature were stirred vigorously with a magnetic stirring bar overnight. The magnesium was then covered with dry diethyl ether and to the suspension was added 1,2-dibromoethane (50  $\mu$ L). A cold bath was then applied followed by dropwise addition of 1-Bromomethyl-2-methoxy-benzene (18.18 g, 5 equiv.) in diethyl ether (71 mL) at a which maintained the temperature at up to 15  $^{\circ}$ C. The  
15 resulting black suspension was stirred at room temperature for 30 minutes and cooled down at  $-20^{\circ}$ C. A solution of (4-Benzyl-morpholin-2-yl)-phenyl-methanone (4g, 1 equiv.) in diethyl ether (50 mL) was then added dropwise *via canula*. The reaction mixture was left to warm to room temperature over two hours and then  
20 quenched by addition of aqueous saturated solution of NaHCO<sub>3</sub> (50 mL). The aqueous solution was extracted with diethyl ether, the organic phase dried with MgSO<sub>4</sub>, evaporated *in vacuo* to give 7 g of a yellow amorphous solid. The compound was taken without further purification in the next step. FIA [M+H]<sup>+</sup>=404.

25

b) 2-(2-Methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride.




To a solution of 1-(4-Benzyl-morpholin-2-yl)-2-(2-methoxy-phenyl)-1-phenyl-ethanol (1 g, 1 equiv.) in ethyl acetate (100 mL) at room temperature under nitrogen atmosphere was added ammonium formate (3.9 g, 25 equiv.) followed by addition of palladium on charcoal (10 %, 1g.). The reaction mixture was heated to reflux for 1 hour, cooled to room temperature and then filtered through Celite. All volatiles were evaporated under *vacuum*, and the resulting solid was purified via preparative HPLC. The isolated white solid was taken up in ethanol. Hydrogen chloride was added (large excess of 2M solution in diethyl ether) and the mixture was stirred until it became a clear solution. Then all the volatiles were evaporated in vacuo, to give 650 mg of the title compound as white solid (75 %). <sup>1</sup>H NMR (300MHz, DMSO D6) δ: 2.43-2.51 (m, 2H), 2.77-2.92 (m, 2H), 3.15-3.23 (m, 3H), 3.41 (s, 3H), 4.10-4.19 (m, 2H), 6.66-6.72 (m, 2H), 6.98-7.07 (m, 2H), 7.13-7.20 (m, 5H), 9.32 (bs, 2H). LCMS (12 minute method) [M+H]<sup>+</sup>=314 @ Rt 3.96 min. single major peak.

### Example 2

#### Preparation of (S, R) 2-(2-Ethoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride.


a) 1-(4-Benzyl-morpholin-2-yl)-2-(2-ethoxy-phenyl)-1-phenyl-ethanol.





The procedure for the synthesis of example 1a, 1-(4-Benzyl-morpholin-2-yl)-2-(2-methoxy-phenyl)-1-phenyl-ethanol, was followed using commercially available 2-ethoxybenzylmagnesium bromide (from Rieke-Metals) as starting material and making non-critical variations, to yield the title compound. FIA  
5  $[M+H]^+=418$ .

**b) 2-(2-Ethoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride.**




The procedure for the synthesis of example 1b, 2-(2-Methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride was followed making non-critical  
10 variations, to yield the title compound.  $^1\text{H}$  NMR (300MHz, DMSO D6)  $\delta$ : 1.11 (t, 3H,  $J=6.97\text{Hz}$ ), 2.43-2.56 (m, 1H), 2.81-2.96 (m, 2H), 3.17-3.27 (m, 3H), 3.55-3.67 (m, 2H), 3.84-3.92 (m, 1H), 4.05-4.20 (m, 2H), 6.68-6.74 (m, 2H), 7.01-7.18 (m, 8H), 8.92 (bs, 2H) ppm. LCMS (12 minute method)  $[M+H]^+=328$  @  $R_t$  4.57 min.  
15 single major peak.

**Example 3**

**Preparation of (S, R) 2-(2-Isopropoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride.**


20

**a) 1-(4-Benzyl-morpholin-2-yl)-2-(2-isopropoxy-phenyl)-1-phenyl-ethanol.**



Solid magnesium turnings (4.6 g, 48 equiv.) under nitrogen atmosphere at room temperature were stirred vigorously with a magnetic stirring bar overnight. The magnesium was then covered with dry tetrahydrofuran. A cold bath was then applied followed by dropwise addition of 1-chloromethyl-2-isopropoxy-benzene (3.0 g, 4 equiv.) in tetrahydrofuran (40 mL). During slow addition of the electrophile no exotherm was observed so on completion of addition 3 crystals of Iodine were added to promote initiation of the reaction. After this addition the reaction temperature was allowed to spike to 50 °C then cooled rapidly to 8 °C before being left to warm to room temperature for one hour. The resulting black suspension was cooled down to -10 °C and a solution of (4-Benzyl-morpholin-2-yl)-phenyl-methanone (1.2 g, 1 equiv.) in tetrahydrofuran (10 mL) was then added dropwise. The reaction mixture was left to warm to room temperature over thirty minutes and then quenched by addition of aqueous saturated solution of NaHCO<sub>3</sub> (50 mL) prior to filtration through Celite. The aqueous solution was extracted with diethyl ether, the organic phase dried with MgSO<sub>4</sub>, evaporated *in vacuo* to give 3 g of a yellow amorphous solid. The compound was taken without further purification in the next step. LCMS (6 minutes method) [M+H]<sup>+</sup>=432 @ Rt 3.25 min. major peak.

**b) 2-(2-Isopropoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride.**




The procedure for the synthesis of example 1b, 2-(2-Methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride was followed making non-critical variations, to yield the title compound. <sup>1</sup>H NMR (300MHz, MeOH D<sub>3</sub>) δ: 1.12-1.16 (m, 6H), 2.51-2.55 (m, 1H), 2.89-3.14 (m, 4H), 3.56-3.60 (m, 1H), 3.82-3.92 (m,

1H), 3.99-4.03 (m, 1H), 4.17-4.22 (m, 1H), 4.36-4.44 (m, 1H), 6.50-6.55 (m, 1H), 6.66-6.73 (m, 2H), 6.92-6.98 (m, 1H), 7.07-7.20 (m, 5H) ppm. LCMS (12 minutes method)  $[M+H]^+ = 342$  @ Rt 4.90 min. major peak.

5 Example 4


Preparation of (S, R) 1-(3-Fluoro-phenyl)-2-(2-methoxy-phenyl)-1-morpholin-2-yl-ethanol hydrochloride

10 a) 1-(4-Benzyl-morpholin-2-yl)-1-(3-fluoro-phenyl)-2-(2-methoxy-phenyl)-ethanol.



A magnetically stirred 0.25M tetrahydrofuran solution of commercially available 2-methoxybenzylmagnesium bromide (from Rieke-Metals) (80ml, 3equiv.) under nitrogen atmosphere was cooled to -10 °C and to this was added neat (4-Benzyl-morpholin-2-yl)-1-(3-fluoro-phenyl)-methanone (2.1g, 1equiv.). The solution was allowed to warm to room temperature and reaction progress followed using mass spectrometry. After 1.5 hours 2-methoxybenzylmagnesium bromide solution (14ml, 0.5equiv.) was again added to the reaction and after a further 0.5 hours an aqueous saturated solution of NaHCO<sub>3</sub> (50 mL) was added to halt the reaction. The aqueous solution was extracted with diethyl ether, the organic phase dried with MgSO<sub>4</sub>, evaporated *in vacuo* to give 2.8 g of a yellow amorphous solid. The compound was taken without further purification in the next step. LCMS (6 minutes method)  $[M+H]^+ = 422$  @ Rt 3.03 and 2.86 min. major peaks.

25 b) (S, R)-1-(3-Fluoro-phenyl)-2-(2-methoxy-phenyl)-1-morpholin-2-yl-ethanol hydrochloride.




ClH

To a solution of 1-(4-Benzyl-morpholin-2-yl)-1-(3-fluoro-phenyl)-2-(2-methoxy-phenyl)-ethanol (2.8 g, 1 equiv.) in ethyl acetate (100 mL) at room temperature under nitrogen atmosphere was added ammonium formate (4.3 g, 10 equiv.) followed by addition of palladium on charcoal (10 %, 2.7g.). The reaction mixture was heated to reflux for 1 hour, cooled to room temperature and then filtered through Celite. All volatiles were evaporated under *vacuum*, and the resulting solid was purified via preparative HPLC to give the desired diastereoisomers. The active enantiomer was obtained after a further preparative chiral HPLC separation. The active enantiomer, a white solid, was next taken up in ethanol and hydrogen chloride was added (large excess of 2M solution in diethyl ether) and the mixture was stirred until it became a clear solution. Then all the volatiles were evaporated in vacuo, to give 447mg of the title compound as white solid. <sup>1</sup>H NMR (300MHz, DMSO D6)  $\delta$ : 2.49-2.53 (m, 1H), 2.80-2.93 (m, 2H), 3.12-3.33 (m, 4H), 3.41 (s, 3H), 3.85-3.92 (m, 1H), 4.07-4.20 (m, 2H), 6.70-6.75 (m, 2H), 6.92-7.10 (m, 5H), 7.20-7.27 (m, 1H), 9.08 (bs, 2H). LCMS (12 minutes method) [M+H]<sup>+</sup>=332. Rt 4.11min.

Example 5


Preparation of (S, R) 1-Morpholin-2-yl-1-phenyl-2-(2-trifluoromethoxy-phenyl)-ethanol hydrochloride

a) 1-(4-Benzyl-morpholin-2-yl)-1-phenyl-2-(2-trifluoromethoxy-phenyl)-ethanol.



The procedure for the synthesis of example 1a, 1-(4-Benzyl-morpholin-2-yl)-2-(2-methoxy-phenyl)-1-phenyl-ethanol, was followed using 2-(trifluoromethoxy)benzyl bromide (from Fluorochem) as starting material and making non-critical variations, to yield the title compound. FIA  $[M+H]^+=458$ .

**b) (S, R) 1-Morpholin-2-yl-1-phenyl-2-(2-trifluoromethoxy-phenyl)-ethanol hydrochloride.**



10


To a solution of 1-(4-Benzyl-morpholin-2-yl)-1-phenyl-2-(2-trifluoromethoxy-phenyl)-ethanol (7 g, 1 equiv.) in dry 1,2-dichloroethane (40 mL) at 0 °C under nitrogen atmosphere was added ACE-Cl (20.33 g, 10 equiv.). The reaction mixture was left to warm to room temperature for 48 hours. All volatiles were evaporated under vacuum, and the resulting solid was taken-up with methanol (50 mL) and stirred at room temperature overnight. The solution was filtered through acid ion exchange column and the required fractions evaporated to dryness. The resulting solid was taken up with acetonitrile and the insoluble material filtered off. The mother liquor was concentrated in vacuo and purified via preparative HPLC. Both fractions were mixed (from slurry and from HPLC) and taken up in ethanol. Hydrogen chloride was added (large excess of 2M solution in diethyl ether) and the mixture stirred. Then all the volatiles were evaporated in vacuo, to give 1.9 g of the title compound as a white solid (33 %).  $^1\text{H}$  NMR (300MHz, DMSO D6)  $\delta$ : 2.45-2.50 (m, 1H), 2.81-2.97 (m, 2H), 3.18-3.30 (m, 3H), 3.89-3.97 (m, 1H), 4.15-

4.18 (m, 2H), 7.02-7.29 (m, 9H), 9.18 (bs, 2H). LCMS (12 minutes method)  
[M+H]<sup>+</sup>=368 @ Rt 4.88 min. single major peak.

Example 6

5 Preparation of (S, R) 2-Biphenyl-2-yl-1-morpholin-2-yl-1-phenyl-ethanol  
hydrochloride

a) 1-(4-Benzyl-morpholin-2-yl)-2-biphenyl-2-yl-1-phenyl-ethanol.




10

1-(4-Benzyl-morpholin-2-yl)-2-(2-bromo-phenyl)-1-phenyl-ethanol (0.50 g, 1.0 equiv.) and boronic acid (0.402 g, 3.0 equiv.) were suspended in a mixture ethanol/water (2/1, 7.5 mL) and Pd(Ph<sub>3</sub>)<sub>4</sub> (0.022 g, 0.04 equiv.), then K<sub>2</sub>CO<sub>3</sub> (0.654 g, 4.30 equiv.) were added. The mixture was heated to 80°C under nitrogen atmosphere. After 16 hours, the reaction was cooled down to room temperature and filtered through Celite, then extracted with ethyl acetate. The organic layers were combined, dried with MgSO<sub>4</sub>, filtered and concentrated in vacuo yielding a yellow oil, which was purified by column chromatography on silica gel (10% EtOAc:Hexane) to give 0.491g (98%) of the title compound as a white solid.

20

b) (S, R) 2-Biphenyl-2-yl-1-morpholin-2-yl-1-phenyl-ethanol  
hydrochloride.




The procedure for the synthesis of example 1, 2-(2-methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride, was followed making non-critical variations, to yield the title compound. <sup>1</sup>H NMR (300MHz, DMSO D6) δ: 2.16-2.20 (m, 1H), 2.54-2.62 (m, 1H), 2.67-2.76 (m, 1H), 2.85-2.89 (m, 1H), 3.24 (s, 2H), 3.61-3.69 (m, 2H), 3.93-3.98 (m, 1H), 5.14 (bs, 1H), 6.80-6.92 (m, 5H), 7.04-7.17 (m, 5H), 7.27-7.30 (m, 3H), 7.36-7.39 (m, 1H). LCMS (12 minutes method) [M+H]<sup>+</sup>=360 @ Rt 5.15 min. single major peak.

#### Example 7


#### Preparation of (S, R) 2-(2-Chloro-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride

#### a) 1-(4-Benzyl-morpholin-2-yl)-2-(2-chloro-phenyl)-1-phenyl-ethanol.



The procedure for the synthesis of example 1a, 1-(4-Benzyl-morpholin-2-yl)-2-(2-methoxy-phenyl)-1-phenyl-ethanol, was followed using 2-chlorobenzyl chloride (from Aldrich) as starting material and making non-critical variations, to yield the title compound. FIA [M+H]<sup>+</sup>=408 and 410.

b) (S, R) 2-(2-Chloro-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride




The procedure for the synthesis of example 5b, (S, R) 1-Morpholin-2-yl-1-phenyl-2-(2-trifluoromethoxy-phenyl)-ethanol hydrochloride, was followed making non-critical variations, to yield the title compound. <sup>1</sup>H NMR (300MHz, DMSO D6)  $\delta$ : 2.45-2.54 (m, 1H), 2.84-2.93 (m, 2H), 3.17-3.22 (m, 1H), 3.33-3.38 (m, 3H), 3.89-3.97 (m, 1H), 4.14-4.18 (m, 2H), 7.06-7.11 (m, 2H), 7.15-7.26 (m, 7H), 9.24 (bs, 2H) ppm. LCMS (12 minutes method) [M+H]<sup>+</sup>=318-320 @ Rt 4.36 min. single peak.

Example 8

Preparation of (S, R) 2-(5-Fluoro-2-methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride


a) 1-(4-Benzyl-morpholin-2-yl)-2-(5-fluoro-2-methoxy-phenyl)-1-phenyl-ethanol.



The procedure for the synthesis of example 1a, 1-(4-Benzyl-morpholin-2-yl)-2-(2-methoxy-phenyl)-1-phenyl-ethanol, was followed making non-critical variations, to yield the title compound which was taken without further purification in the next step. LCMS (6 minutes method) [M+H]<sup>+</sup>=422 @ Rt 2.85 min. major peak.



b) (S, R) 2-(5-Fluoro-2-methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride




The procedure for the synthesis of 1b, 2-(2-Methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride was followed making non-critical variations, to yield the title compound. <sup>1</sup>H NMR (300MHz, DMSO D6) δ: 2.44-2.50 (m, 1H), 2.79-2.96 (m, 2H), 3.15-3.20 (m, 2H), 3.27-3.33 (m, 2H), 3.42 (s, 3H), 3.86-3.94 (m, 1H), 4.09-4.18 (m, 2H), 6.66-6.71 (m, 1H), 6.80-6.90 (m, 2H), 7.14-7.23 (m, 5H), 9.20 (bs, 2H). LCMS (12 minutes method) [M+H]<sup>+</sup>=332.

10

Example 9

Preparation of (S, R) 1-Morpholin-2-yl-1-phenyl-2-(2-trifluoromethylsulfanyl-phenyl)-ethanol acetate

15 a) 1-(4-Benzyl-morpholin-2-yl)-1-phenyl-2-(2-trifluoromethylsulfanyl-phenyl)-ethanol.




The procedure for the synthesis of example 1a, 1-(4-benzyl-morpholin-2-yl)-2-(2-methoxy-phenyl)-1-phenyl-ethanol, was followed using 1-bromomethyl-2-trifluoromethylsulfanyl-benzene as starting material and making non-critical variations, to yield the title compound. <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>) δ: 2.05-2.33 (m, 3H), 2.49-2.65 (m, 1H), 3.10-3.35 (m, 2H), 3.43-3.55 (m, 1H), 3.67-3.89 (m, 2H),

20

3.91-4.08 (m, 2H), 4.09-4.22 (m, 1H), 6.91-7.05 (m, 1H), 7.10-7.42 (m, 7H), 7.50-7.63 (m, 1H) ppm.

b) (S, R) 1-Morpholin-2-yl-1-phenyl-2-(2-trifluoromethylsulfanyl-phenyl)-ethanol acetate




To a solution of 1-(4-benzyl-morpholin-2-yl)-1-phenyl-2-(2-trifluoromethylsulfanyl-phenyl)-ethanol (218 mg g, 1 equiv.) and solid supported Hunig's base (from Argonaut, 1g, 5 equiv.) in dry tetrahydrofuran (4 mL) at 0 °C under nitrogen atmosphere was added ACE-Cl (502 µL, 10 equiv.). The reaction mixture was left to warm to room temperature for 48 hours. All volatiles were evaporated under vacuum, and the resulting solid was taken-up with methanol (50 mL) and stirred at room temperature overnight. The solution was filtered through acid ion exchange column and the required fractions evaporated to dryness. The resulting solid was purified *via* preparative HPLC to give 62 mg of the title compound as a colourless oil. <sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>) δ: 2.01 (s, 3H), 2.43-2.47 (m, 1H), 2.63-2.70 (m, 1H), 2.81-2.94 (m, 2H), 3.24 (d, 1H, J=13.57Hz), 3.85-3.96 (m, 2H), 4.01-4.05 (m, 1H), 4.09-4.13 (m, 1H), 4.45 (bs, 4H), 6.90-6.93 (m, 1H), 7.13-7.26 (m, 7H), 7.55-7.58 (m, 1H) ppm. LCMS (12 minute method) [M+H]<sup>+</sup>=384 @ Rt 5.13 min. single peak.

### Example 10


#### Preparation of (S, R) 1-Morpholin-2-yl-1-phenyl-2-(2-trifluoromethyl-phenyl)-ethanol

a) 4-Benzyl-2-(2-phenyl-oxiranyl)-morpholine.



To a mixture of trimethylsulfoxonium iodide (783 mg, 1equiv.) and sodium hydride (142 mg, 1 equiv.) in dimethylformamide (17 mL) at 0 °C under nitrogen atmosphere was added dimethylsulfoxide (251  $\mu$ L, 1 equiv.) and the resulting suspension was stirred for 30 minutes. A solution of (4-Benzyl-morpholin-2-yl)-phenyl-methanone (1 g, 1equiv.) in dimethylformamide (10 mL) was then added dropwise. Stirring was continued for 30 minutes and the reaction was stopped by addition of water (50 mL). The aqueous solution was extracted with diethyl ether, the organic phase dried with  $\text{MgSO}_4$ , and evaporated *in vacuo*. The crude material was purified using a column chromatography on silica gel eluting with a mixture of ethyl acetate/heptane (20/80) to give 825 mg of the title compound as a colourless oil (78 %), mixture of two diastereoisomers.


b) 1-(4-Benzyl-morpholin-2-yl)-1-phenyl-2-(2-trifluoromethyl-phenyl)-ethanol.



To a suspension of magnesium turnings in tetrahydrofuran (2mL) at room temperature under nitrogen atmosphere was added a solution 1-Bromo-2-trifluoromethyl-benzene (7.6g, 5equiv.) in tetrahydrofuran (32 mL) and the mixture was stirred for an hour. The solution was cooled to -78 °C and copper iodide (646 mg) was added followed by dropwise addition of a solution of 4-Benzyl-2-(2-phenyl-oxiranyl)-morpholine (2g, 1 equiv.) in tetrahydrofuran (10 mL). The resulting mixture was warmed to room temperature over 2 hours and then treated

with water (10 mL). The solution was extracted with diethyl ether, the organic phase dried with  $\text{MgSO}_4$ , and evaporated *in vacuo*. The crude material was purified using a column chromatography on silica gel eluting with a mixture of ethyl acetate/heptane (10/90) to give 352 mg of the title compound as a colourless oil (12 %). LCMS (6 minutes method)  $[\text{M}+\text{H}]^+=442$  @ Rt 3.05 min. major peak.

c) (S, R) 1-Morpholin-2-yl-1-phenyl-2-(2-trifluoromethyl-phenyl)-ethanol




To a solution of 1-(4-Benzyl-morpholin-2-yl)-1-phenyl-2-(2-trifluoromethyl-phenyl)-ethanol (352 mg, 1 equiv.) in ethanol (15 mL) at room temperature under nitrogen atmosphere was added ammonium formate (507 mg, 10 equiv.) followed by addition of palladium on charcoal (10 %, 355 mg.). The reaction mixture was heated to reflux for 1 hour, cooled to room temperature and then filtered through Celite. All volatiles were evaporated under vacuum to give 265 mg of the title compound as white solid (94 %). The enantiomeric mixture was resolved using chiral HPLC, to give the title compound as a single enantiomer.  $^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ )  $\delta$ : 1.62 (bs, 4H), 2.25-2.30 (m, 1H), 2.56-2.64 (m, 1H), 2.75-2.87 (m, 2H), 3.18 (d, 1H,  $J=14.88\text{Hz}$ ), 3.71-3.81 (m, 2H), 3.89 (d, 1H,  $J=14.88\text{Hz}$ ), 4.02-4.05 (m, 1H), 6.83-6.86 (m, 1H), 7.09-7.34 (m, 7H), 7.53-7.55 (m, 1H) ppm. LCMS (12 minute method)  $[\text{M}+\text{H}]^+=352$  @ Rt 4.73 min. single peak.

Example 11

Preparation of (S, R) 2-(2-Chloro-phenyl)-1-(3-fluoro-phenyl)-1-morpholin-2-yl-ethanol hydrochloride


25

a) 1-(4-Benzyl-morpholin-2-yl)-2-(2-chloro-phenyl)-1-(3-fluoro-phenyl)-ethanol.



The procedure for the synthesis of **4a**, 1-(4-Benzyl-morpholin-2-yl)-1-(3-fluoro-phenyl)-2-(2-methoxy-phenyl)-ethanol was followed using 2-chlorobenzyl chloride as starting material, and making non-critical variations, to yield the title compound which was taken without further purification in the next step. LCMS (6 minutes method)  $[M+H]^+=426$  @ Rt 2.85 min. major peak.

**b) (S, R) 2-(2-Chloro-phenyl)-1-(3-fluoro-phenyl)-1-morpholin-2-yl-ethanol hydrochloride**



10


To a solution of 1-(4-Benzyl-morpholine-2-yl)-2-(2-chloro-phenyl)-1-(3-fluoro-phenyl)-ethanol. (3.2g, 1 equiv.) in dry 1,2-dichloroethane (40 mL) under nitrogen atmosphere was added ACE-Cl (20.33 g, 5 equiv.). The reaction mixture was stirred at room temperature overnight then refluxed until completion. All volatiles were evaporated under vacuum, and the resulting residue redissolved in acetonitrile. This solution was filtered through an ion exchange column and the filtrate taken-up with methanol (50 mL) and refluxed for 3h. The solution was again filtered through acid ion exchange column and the required fractions evaporated to dryness. The resulting solid was next purified via preparative HPLC followed by chiral HPLC. The purified active enantiomer was taken up in ethanol and hydrogen chloride was added (large excess of 2M solution in diethyl ether) and the mixture stirred. Then all the volatiles were evaporated in vacuo, to give 519mg of the title compound as a white solid (18 %).  $^1\text{H}$  NMR (300MHz, DMSO D6)  $\delta$ : 2.43-2.54

(m, 1H), 2.81-2.95 (m, 2H), 3.16-3.23 (m, 1H), 3.30-3.44 (m, 2H), 3.54 (bs, 1H), 3.92-4.00 (m, 1H), 4.15-4.23 (m, 2H), 6.96-7.29 (m, 8H), 9.32-9.45 (m, 2H). LCMS (12 minute method)  $[M+H]^+ = 336$ .

5 **Example 12**

**Preparation of (S, R) 1-Morpholin-2-yl-1-phenyl-2-*o*-tolyl-ethanol hydrochloride**


a) **1-(4-Benzyl-morpholin-2-yl)-1-phenyl-2-*o*-tolyl-ethanol.**



10 The procedure for the synthesis of example 1a, 1-(4-benzyl-morpholin-2-yl)-2-(2-methoxy-phenyl)-1-phenyl-ethanol, was followed using commercially available 2-methylbenzylmagnesium bromide (from Rieke-Metals) as starting material and making non-critical variations, to yield the title compound. FIA  $[M+H]^+ = 388$ .

15

b) **(S, R) 1-Morpholin-2-yl-1-phenyl-2-*o*-tolyl-ethanol hydrochloride**



The procedure for the synthesis of example 1b, 2-(2-methoxy-phenyl)-1-morpholin-2-yl-1-phenyl-ethanol hydrochloride was followed making non-critical variations, to yield the title compound.  $^1\text{H}$  NMR (300MHz, DMSO D6)  $\delta$ : 1.62 (s, 3H), 2.40-2.58 (m, 1H), 2.78-3.01 (m, 2H), 3.03-3.09 (m, 1H), 3.15-3.31 (m, 2H),

20

3.90-4.05 (m, 1H), 4.15-4.25 (m, 2H), 6.89-7.28 (m, 9H), 9.21-9.55 (m, 2H).  
LCMS  $[M+H]^+ = 298$  single peak.

The compounds of the present invention may be used as medicaments in  
5 human or veterinary medicine. The compounds may be administered by various  
routes, for example, by oral or rectal routes, topically or parenterally, for example  
by injection, and are usually employed in the form of a pharmaceutical composition.

Such compositions may be prepared by methods well known in the  
pharmaceutical art and normally comprise at least one active compound in  
10 association with a pharmaceutically acceptable diluent or carrier. In making the  
compositions of the present invention, the active ingredient will usually be mixed  
with a carrier or diluted by a carrier, and/or enclosed within a carrier which may, for  
example, be in the form of a capsule, sachet, paper or other container. Where the  
carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts  
15 as a vehicle, excipient or medium for the active ingredient. Thus, the composition  
may be in the form of tablets, lozenges, sachets, cachets, elixirs, suspensions,  
solutions, syrups, aerosol (as a solid or in a liquid medium), ointments containing,  
for example, up to 10% by weight of the active compound, soft and hard gelatin  
capsules, suppositories, injection solutions and suspensions and sterile packaged  
20 powders.

Some examples of suitable carriers are lactose, dextrose, vegetable oils,  
benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin,  
carbohydrates such as starch and petroleum jelly, sucrose sorbitol, mannitol,  
starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl  
25 cellulose, methyl- and propyl- hydrobenzoate, talc, magnesium stearate and mineral  
oil. The compounds of formula (I) can also be lyophilized and the lyophilizates  
obtained used, for example, for the production of injection preparations. The  
preparations indicated can be sterilized and/or can contain auxiliaries such as  
lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for  
30 affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one  
or more further active compounds, e.g. one or more vitamins. Compositions of the  
invention may be formulated so as to provide, quick, sustained or delayed release of

the active ingredient after administration to the patient by employing procedures well known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 500 mg, more usually about 25 to about 5 300 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary doses for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.

The pharmacological profile of the present compounds may be demonstrated 10 as follows.

Scintillation proximity assays for determining the affinity of test ligands at the norepinephrine transporter.

The compounds of the invention are norepinephrine reuptake inhibitors, and 15 possess excellent activity in, for example, a scintillation proximity assay (e.g. J. Gobel, D.L. Saussy and A. Goetz, J. Pharmacol. Toxicol. (1999), 42, 237-244). Thus <sup>3</sup>H-nisoxetine binding to norepinephrine re-uptake sites in a cell line transfected with human norepinephrine transporter binding has been used to determine the affinity of ligands at the norepinephrine transporter.

20

Acid Stability

The acid stability of a compound according to the present invention was determined as a solution in buffer at 6 different pH values (HCl 0.1N, pH 2, pH 4, pH 6, pH 7, and pH 8) at 40°C over a time course of 72 hours. Samples were taken 25 at the beginning of the study and after 3, 6 and 24 hours and analysed by capillary electrophoresis. The original sample used in this study contained 0.8% of the undesired epimer as internal standard. The samples taken at the different time points during the study did not show any significant change in the percentage of the undesired epimer. This confirms that the compound is chemically and 30 configurationally stable under acidic conditions.



**In Vitro Determination of the Interaction of compounds with CYP2D6 in Human Hepatic Microsomes**

**Principle:**

- 5           The interaction of compounds with CYP2D6 was evaluated by the measurement of the inhibition of the bufuralol 1'-hydroxylase activity by the compounds.

**Assay description:**

- 10           Bufuralol 1-hydroxylase activity is determined by using 0.5 mg/ml human liver microsomal protein (human biologics), 10  $\mu$ mol/L bufuralol, in 0.1 M sodium phosphate buffer pH 7.4, incubated for 5 min at 37°C in the presence of 2 mM  $\beta$ NADPH, with 0, 5 or 25  $\mu$ M of the test compound (inhibitor). The compound was dissolved in acetonitrile, such that the final concentration of acetonitrile in the
- 15           incubation was 0.5%. The total reaction volume was 100  $\mu$ l. The reaction was terminated by addition of 75  $\mu$ l of methanol followed by centrifugation. 40  $\mu$ l of the supernatant was analysed by HPLC.

**Analysis conditions:**

- 20           A Beckman Ultrasphere C<sub>18</sub> column (5  $\mu$ m, 250 x 4.6 mm) was used, with a 13 minute gradient from 100% of solvent A (0.02 M potassium dihydrogen phosphate buffer pH 3/methanol (65/35)) to 100 % of solvent B (0.02 M potassium dihydrogen phosphate buffer pH 3/methanol (20/80)), according to the following gradient. The run time was 20 minutes. Formation of 1'-hydroxybufuralol was
- 25           detected by fluorimetric detection with extinction at  $\lambda$  252 nm and emission at  $\lambda$  302 nm.

|    | Time (min) | Solvent A (%) | Solvent B (%) |
|----|------------|---------------|---------------|
|    | 0          | 100           | 0             |
|    | 8          | 0             | 100           |
| 30 | 12         | 0             | 100           |
|    | 13         | 100           | 0             |

**Calculation of the results:**

The percent of inhibition is calculated as follows:


$$100 - \frac{100 \times 1'\text{-hydroxybufuralol area formed with inhibitor}}{1'\text{-hydroxybufuralol area formed without inhibitor}}$$

5 The IC<sub>50</sub> is calculated from the percent inhibition as follows (assuming competitive inhibition):  $\frac{\text{Compound Concentration} \times (100 - \text{Percent of inhibition})}{\text{Percent of inhibition}}$

The IC<sub>50</sub> estimation is assumed valid if inhibition is between 20% and 80% (Moody 1999).

## CLAIMS

1. A compound of formula (I)



5 wherein

Rx is H;

Ry is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

each Rz is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;


X represents O;

10 Y represents OH or OR;

R is C<sub>1</sub>-C<sub>4</sub> alkyl; and

Ar<sub>1</sub> and Ar<sub>2</sub> are each independently selected from the group consisting of phenyl, and substituted phenyl; and pharmaceutically acceptable salts thereof.

- 15 2. A compound as claimed in claim 1, represented by the formula II



wherein R<sub>1</sub> and R<sub>2</sub> are each independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo and phenyl; and

R<sub>3</sub> is selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl; and pharmaceutically acceptable salts thereof.

20

3. A compound as claimed in claim 2, wherein  $R_1$  is selected from  $C_1$ - $C_4$  alkyl,  $O(C_1$ - $C_4$  alkyl), F and Ph.

4. A compound as claimed in claim 3, wherein  $R_2$  is H.

5. A compound as claimed in claim 4, wherein  $R_3$  is H.

6. A compound as claimed in any one of claims 1-5, for use as a pharmaceutical.

7. A compound as claimed in any one of claims 1-5, for use as a selective inhibitor of the reuptake of norepinephrine.

8. The use of a compound as claimed in any one of claims 1-5, for treating a disorder associated with norepinephrine dysfunction in mammals.

9. The use of a compound as claimed in any one of claims 1-5, for the manufacture of a medicament for treating a disorder associated with norepinephrine dysfunction in mammals.

10. A method for selectively inhibiting the reuptake of norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1-5, or a pharmaceutically acceptable salt thereof.

11. a method for treating disorders associated with norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1-5, or a pharmaceutically acceptable salt thereof.


12. A method or use as claimed in any one of claims 8, 9 and 11, wherein the disorder is selected from nervous system conditions selected from the

group consisting of an addictive disorder and withdrawal syndrome, an adjustment disorder, an age-associated learning and mental disorder, anorexia nervosa, apathy, an attention-deficit disorder (ADD) due to general medical conditions, attention-deficit hyperactivity disorder (ADHD), bipolar disorder, bulimia nervosa, chronic  
5 fatigue syndrome, chronic or acute stress, conduct disorder, cyclothymic disorder, depression, dysthymic disorder, fibromyalgia and other somatoform disorders, generalized anxiety disorder, incontinence, an inhalation disorder, an intoxication disorder, mania, migraine headaches, obesity, obsessive compulsive disorders and related spectrum disorders, oppositional defiant disorder, panic disorder, peripheral  
10 neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, a psychotic disorder, seasonal affective disorder, a sleep disorder, social phobia, a specific developmental disorder, selective serotonin reuptake inhibition (SSRI) "poop out" syndrome, TIC disorders, cognitive disorders including mild cognitive impairment (MCI), dementia of the Alzheimers type (DAT), vascular dementia and  
15 cognitive impairment associated with schizophrenia (CIAS), hypotensive states including orthostatic hypotension, and pain including chronic pain, neuropathic pain and antinociceptive pain.

13. A method or use as claimed in any one of claims 8, 9 and 11,  
20 wherein the disorder is attention deficit hyperactivity disorder, ADHD.

**ABSTRACT**

A compound of formula (I)



wherein

R<sub>x</sub> is H;

R<sub>y</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

10 each R<sub>z</sub> is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

X represents O;

Y represents OH or OR;

R is C<sub>1</sub>-C<sub>4</sub> alkyl; and

15 Ar<sub>1</sub> and Ar<sub>2</sub> are each independently selected from the group consisting of phenyl,  
and substituted phenyl; and pharmaceutically acceptable salts thereof.